[pending] NIACIN (NIACIN)
Pending LLM rewrite. Source: FDA_DRUG D-0158-2026.
- Product
- NIACIN — NIACIN (NIACIN)
- Category
- Drug
- Distribution
- Distributed nationwide
Category
FDA recalls of prescription and over-the-counter drugs.
FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.
The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.
If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.
Pending LLM rewrite. Source: FDA_DRUG D-0158-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0153-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0152-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0154-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0155-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0151-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0121-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0102-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0108-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0107-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0148-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0131-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0115-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0118-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0129-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0149-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0141-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0114-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0135-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0120-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0127-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0109-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0147-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0103-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0110-2026.
Looking for a different category? Browse all recalls.